Aptamer-2

An anti-Spike (SARS-CoV-2) aptamer.

Phase of research

Potential treatment - pre-clinical evidence

How it helps

Antiviral

Drug status

Experimental

1
Supporting references
0
Contradictory references
0
AI-suggested references
0
Clinical trials

General information

Aptamer-2 is a synthetic ssDNA aptamer selected for its affinity for SARS-CoV-2 Spike protein/RBD using SELEX (Liu et al., 2021).

 


Supporting references

Link Tested on Impact factor Notes Publication date
Neutralizing aptamers block S/RBD‐ACE2 interactions and prevent host cell infection
Spike protein ACE2 DNA Biophysical assay In vitro
in vitro binding assay; in vitro biophysical assay; ACE-293T cells; Vero E6 cells; SARS-CoV-2 Spike pseudovirus; SARS-CoV-2 strain USA-WA1/2020 12.96

Aptamer-2 bound SARS-CoV-2 Spike protein/RBD in vitro, blocked its interaction with host ACE2 receptor and neutralized SARS-CoV-2 Spike pseudotyped virus with an IC50 of 53 nM. The aptamer also protected Vero E6 cell from live virus infection.

Mar/08/2021